Literature DB >> 2884932

Effect of sulphasalazine on the radiological progression of rheumatoid arthritis.

T Pullar, J A Hunter, H A Capell.   

Abstract

We have investigated the influence of sulphasalazine, a second line antirheumatic drug, on the radiological progression of erosions in rheumatoid arthritis over a two year period in 41 patients. Hand radiograph scores deteriorated significantly over this period, but in a group of 31 patients in whom one year films were also available this deterioration was limited to the first year. This slowing of radiological deterioration was not related to 'normalisation' of the erythrocyte sedimentation rate (ESR). Compared with a 'control' group of 10 patients who had refused offers of second line therapy, sulphasalazine treated patients showed less deterioration over the two year period, and this difference was more marked than in previous studies of gold or penicillamine. No significant change was seen in large joint radiographs in sulphasalazine treated patients over two years, but this probably represents the poor sensitivity of the method of assessment. No significant correlation was seen between changes in inflammatory indices and slowing of radiological deterioration in erosion score. Thus sulphasalazine appears to slow the progression of radiological disease of the hands over the second year of treatment in a representative sample of patients who continue to receive treatment for two years.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2884932      PMCID: PMC1002149          DOI: 10.1136/ard.46.5.398

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films.

Authors:  A Larsen; K Dale; M Eek
Journal:  Acta Radiol Diagn (Stockh)       Date:  1977-07

2.  A biochemical assessment of sulphasalazine in rheumatoid arthritis.

Authors:  H A Bird; J S Dixon; M E Pickup; V M Rhind; J R Lowe; M R Lee; V Wright
Journal:  J Rheumatol       Date:  1982 Jan-Feb       Impact factor: 4.666

3.  Progression of radiological changes in rheumatoid arthritis.

Authors:  D L Scott; K A Grindulis; G R Struthers; B L Coulton; A J Popert; P A Bacon
Journal:  Ann Rheum Dis       Date:  1984-02       Impact factor: 19.103

4.  Effects of auranofin on the radiological progression of joint erosion in rheumatoid arthritis.

Authors:  J P Gofton; W M O'Brien
Journal:  J Rheumatol Suppl       Date:  1982 Jul-Aug

5.  Does second-line therapy affect the radiological progression of rheumatoid arthritis?

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Ann Rheum Dis       Date:  1984-02       Impact factor: 19.103

6.  Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy.

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Br J Rheumatol       Date:  1985-08

7.  Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone.

Authors:  K A Grindulis; B McConkey
Journal:  Ann Rheum Dis       Date:  1984-06       Impact factor: 19.103

8.  Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.

Authors:  V C Neumann; K A Grindulis; S Hubball; B McConkey; V Wright
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

9.  Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate.

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

10.  Sulphasalazine in rheumatoid arthritis.

Authors:  B McConkey; R S Amos; S Durham; P J Forster; S Hubball; L Walsh
Journal:  Br Med J       Date:  1980-02-16
View more
  18 in total

Review 1.  Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis.

Authors:  H A Capell; M Brzeski
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

2.  Can treatment with methotrexate influence the radiological progression of rheumatoid arthritis?

Authors:  A A Drosos; A H Karantanas; D Psychos; C Tsampoulas; H M Moutsopoulos
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

3.  "Second line" drugs for rheumatoid arthritis.

Authors:  R D Sturrock
Journal:  BMJ       Date:  1991-07-27

4.  Creative trial design in RA: optimizing patient outcomes.

Authors:  Maya H Buch; Sue Pavitt; Mahesh Parmar; Paul Emery
Journal:  Nat Rev Rheumatol       Date:  2013-02-05       Impact factor: 20.543

Review 5.  The use of disease modifying antirheumatic drugs in the management of rheumatoid arthritis.

Authors:  L E Hart; P Tugwell
Journal:  Postgrad Med J       Date:  1989-12       Impact factor: 2.401

6.  Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.

Authors:  D L Scott; J S Smolen; J R Kalden; L B van de Putte; A Larsen; T K Kvien; M Schattenkirchner; P Nash; C Oed; I Loew-Friedrich
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

Review 7.  Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Ben A C Dijkmans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient?

Authors:  H A Capell; D R Porter; R Madhok; J A Hunter
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

9.  Comparison of phenytoin and gold as second line drugs in rheumatoid arthritis.

Authors:  I M Richards; S M Fraser; J A Hunter; H A Capell
Journal:  Ann Rheum Dis       Date:  1987-09       Impact factor: 19.103

10.  Progressive joint damage during penicillamine therapy for rheumatoid arthritis.

Authors:  D L Scott; A Greenwood; R Bryans; E C Huskisson
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.